MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response
Nantes University Hospital
248 participants
Dec 11, 2025
INTERVENTIONAL
Conditions
Summary
MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response
Eligibility
Inclusion Criteria6
- Age over 18;
- Diagnosis of ADHD confirmed by DIVA-5 interview following a specialized ADHD-addiction(s) consultation;
- Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological);
- Presence of at least one comorbid addictive disorder (SUD and/or BA);
- Having given their consent to take part in the study;
- Being affiliated to the French social security system or benefiting from such a system.
Exclusion Criteria7
- Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data;
- Pregnant or breast-feeding woman;
- Person deprived of liberty;
- Person under compulsory psychiatric care;
- Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome;
- Guardianship or safeguard of justice.
- Patients who consumned psychoactive substances within 12 hours prior to their visit.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The program runs for 16 weeks, with two sessions per week, one with a neuropsychologist. In the first 4 weeks, the patient will have weekly sessions at the center and complete the other session at home using the app provided for the study. For the next 8 weeks, sessions with the neuropsychologist will be every other week, with the other session at home. The neuropsychologist will track progress through the software history and follow up by phone if needed. The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron).
Control program, with the same functional characteristics but without the targeted cognitive functions. For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06906328